Comparative Pharmacology
Head-to-head clinical analysis: ARESTOCAINE HYDROCHLORIDE versus POLOCAINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARESTOCAINE HYDROCHLORIDE versus POLOCAINE.
ARESTOCAINE HYDROCHLORIDE vs POLOCAINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Arestocaine hydrochloride is a local anesthetic of the amide type. It stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthesia.
Local anesthetic that stabilizes the neuronal membrane by inhibiting the influx of sodium ions, thereby blocking nerve impulse propagation.
2-5 mg/kg intramuscularly every 60-90 minutes, not to exceed 500 mg total dose in a 12-hour period.
100 mg orally every 12 hours
None Documented
None Documented
Terminal elimination half-life is approximately 1.5–2 hours in adults with normal hepatic and renal function; prolonged in hepatic impairment or congestive heart failure.
Terminal elimination half-life approximately 1.5-2.0 hours in adults; prolonged to 3-5 hours in hepatic impairment and neonates.
Renal excretion of unchanged drug and metabolites; approximately 90% excreted in urine as parent compound and metabolites (60% as unchanged drug, 30% as metabolites), with less than 10% fecal elimination.
Hepatic metabolism to 2,6-xylidine and 4-hydroxy-2,6-xylidine; <10% excreted unchanged in urine; approximately 70-80% of metabolites excreted renally, with <5% in feces.
Category C
Category C
Local Anesthetic
Local Anesthetic